Sana Biotechnology (SANA) Cash & Equivalents (2020 - 2026)

Sana Biotechnology has disclosed Cash & Equivalents across 7 years of filings, most recently posting $83.8 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $83.8 million, down 12.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $83.8 million (down 12.83% YoY), and the FY2025 annual result was $71.9 million, down 43.66% from the prior year.
• Cash & Equivalents came in at $83.8 million for Q1 2026 at Sana Biotechnology, up from $71.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $194.7 million in Q2 2022 to a low of $6.1 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $133.5 million (2023), against an average of $128.3 million.
• Across the five-year window, Cash & Equivalents sank 97.59% in 2022 and surged 2088.8% in 2023, its largest moves.
• Sana Biotechnology's Cash & Equivalents stood at $6.1 million in 2022, then soared by 2088.8% to $133.5 million in 2023, then declined by 4.46% to $127.6 million in 2024, then tumbled by 43.66% to $71.9 million in 2025, then rose by 16.6% to $83.8 million in 2026.
• The last three Cash & Equivalents figures came in at $83.8 million (Q1 2026), $71.9 million (Q4 2025), and $103.4 million (Q3 2025), per Business Quant data.